Seventure leads €2m round for Domain Therapeutics

French venture player SODIV also invested in the firm alongside existing shareholders Alsace Inter Regio Fonds d'Investissement, IP Growth, Auriga and the company's chairman.

The fresh funding will support the development of strategic commercial alliances and new partnerships.

Previous funding
In 2002, Sofinnova Partners led a €3m round for Domain Therapeutics (then Faust Pharmaceuticals), contributing two thirds of the capital. The remainder of the funding was supplied by Auriga Partners.

In 2008, AGF Private Equity, Auriga Partners, Edmond de Rothschild Investment Partners and Sofinnova Partners injected €2.11m into Domain Therapeutics, alongside new investors Alsace Inter Regio Fonds d'Investissement and Alsace Création.

Company
Founded in 2001 and based in Strasbourg, Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and early development of small molecules targeting G-Protein Coupled Receptors.

The firm currently conducts research into Alzheimer's disease, depression, Parkinson's disease and schizophrenia.

People
Sebastien Groyer is a partner at Seventure. Pascal Neuville is CEO of Domain Therapeutics.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Healthcare
• Expansion
• France
• Seventure (SPEF)